bioRxivImmunology
The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity In Cancer
Abstract
The PD-L1/PD-1 axis was shown to promote tumor growth and progression via the inhibition of anti-tumor immunity. Blocking this axis was shown to be beneficial in maintaining the anti-tumor functions of the adaptive immune system. Still, the consequences of blocking the PD-L1/PD-1 axis on innate immune responses remain largely unexplored. In this context, neutrophils were shown to consist of different subpopulations, which possess either pro- and anti-tumor properties. PD-L1-expressing neutrophils are considered pro-tumor as they can suppress cytotoxic T-cells. That said, we found that PD-L1 expression is not limited to tumor promoting neutrophils but is also evident in anti-tumor neutrophils. We show that neutrophil cytotoxicity is effectively and efficiently blocked by tumor cell expressed PD-1. Furthermore blocking of either neutrophil PD-L1 or tumor cell PD-1 maintains neutrophil cytotoxicity resulting in enhanced tumor cell apoptosis. Importantly, we show that tumor cell PD-1 blocks neutrophil cytotoxicity and promotes tumor growth via a mechanism independent of adaptive immunity. Taken together, these findings highlight the therapeutic potential of enhancing anti-tumor innate immune responses via blocking of the PD-L1/PD-1 axis.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- When killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer
M. S. Hasim, M. Marotel, … M. Ardolino·bioRxiv·Jun 26, 2020
- Inflammasome- and gasdermin D-independent IL-1β production mobilizes neutrophils to inhibit antitumor immunity
M. Kiss, L. Vande Walle, … D. Laoui·bioRxiv·Aug 4, 2020
- PD-L1 ligation on NK cells induces a metabolic shift from glycolysis to fatty acid oxidation, enhancing tumor infiltration and control
Katja Srpan, Kyle B. Lupo, … Katharine C. Hsu·bioRxiv·Jun 27, 2025
- Early dynamics of a neutrophil interferon program drive immunotherapy resistance and limit durable anti-tumor immunity
Yang Gao, Emmanuel Anning, … Xiang H.-F. Zhang·bioRxiv·Oct 1, 2026
- Dendritic cell PD-L2 restrains intratumoral CD8+ T cell immunity
Jinwoo Nah, Amanda Sun, … Chrysothemis C. Brown·bioRxiv·Sep 16, 2026
- Programmed cell death-1 receptor mediated regulation of Tbet+ NK1.1- Innate Lymphoid Cells within the Tumor Microenvironment
M. Lim, C. Lai, … S. Amarnath·bioRxiv·Sep 21, 2022